Search Within

Gynecologic Medicine Service

Formats
  1. Journal Article (1104)
  2. Meeting Abstract (902)
  3. Review (55)
  4. Book Section (46)
  5. Editorial (36)
  6. Guidelines (22)
  7. Correspondence (9)
  8. Miscellaneous (3)
  9. Research Letter (2)
  10. Book Whole (1)
Groups
  1. Solid Tumor Oncology Division (2180)
  2. Department of Medicine (2174)
  3. Gynecology Disease Management Team (1877)
  4. GDMT, Medicine (1859)
  5. Surgery (603)
  6. GDMT, Surgery (479)

More Groups

People
  1. Carol Aghajanian (615)
  2. Nadeem Abu-Rustum (292)
  3. Martee Hensley (290)
  4. Roisin O'Cearbhaill (273)
  5. Vicky Makker (269)
  6. Paul Sabbatini (262)

More People

Years
  1. 2025 (75)
  2. 2024 (167)
  3. 2023 (171)
  4. 2022 (209)
  5. 2021 (163)
  6. 2020 (203)

More Years

Publications
  1. Journal of Clinical Oncology (458)
  2. Gynecologic Oncology (420)
  3. International Journal of Gynecological Cancer (161)
  4. Annals of Oncology (117)
  5. Clinical Cancer Research (71)
  6. Cancer Research (55)

More Publications

Publishers
  1. American Society of Clinical Oncology (498)
  2. Elsevier B.V. (446)
  3. Lippincott Williams & Wilkins (188)
  4. American Association for Cancer Research (173)
  5. Oxford University Press (144)
  6. Elsevier Inc. (128)

More Publishers

Results (2180)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Effect of prior bevacizumab therapy in patients with platinum-sensitive recurrent ovarian carcinoma (ROC) in the phase 3 study ARIEL3
    Meeting Abstract

    Oza, A.; Coleman, R. L.; Lorusso, D.; Aghajanian, C.; Oaknin, A.; Dean, A.; Colombo, N.; Weberpals, J. I.; Clamp, A.; Scambia, G.; more...
    International Journal of Gynecological Cancer (2018)

    Fulltext@MSK | Save
  • A phase III randomized controlled trial of secondary cytoreductive surgery (SCS) followed by platinum-based chemotherapy (PC) platinum-sensitive, recurrent ovarian cancer (PSOC) - Surgical parameters
    Meeting Abstract

    Coleman, R. L.; Enserro, D.; Herzog, T. J.; Sabbatini, P.; Armstrong, D. K.; Kim, B.; Fujiwara, K.; Walker, J. L.; Spirtos, N.; Flynn, P. J.; more...
    International Journal of Gynecological Cancer (2018)

    Fulltext@MSK | Save
  • A phase Ib study of miransertib (ARQ 092) in combination with anastrozole in patients with PIK3CA or AKT1-mutant ER+ endometrial or ovarian cancer
    Meeting Abstract

    Hyman, D.; Bonafede, M.; O'Cearbhaill, R.; Grisham, R.; Zamarin, D.; Tew, W.; Aghajanian, C.; Cadoo, K.; Friedman, C.; Savage, R. E.; more...
    Cancer Research (2018)

    Fulltext@MSK | Save
  • Cell-free DNA sequencing in ERBB2-mutant breast cancer patients treated with neratinib and fulvestrant: Exploratory analysis from the phase 2 SUMMIT 'basket' trial
    Meeting Abstract

    Schram, A. M.; Selcuklu, S. D.; Nagy, R. J.; Smyth, L. M.; Eli, L. D.; Cutler, R. E.; Lalani, A. S.; Hyman, D. M.; Lanman, R. B.
    Cancer Research (2018)

    Fulltext@MSK | Save
  • Germline SDHA mutations in children and adults with cancer
    Journal Article

    Dubard Gault, M.; Mandelker, D.; Delair, D.; Stewart, C. R.; Kemel, Y.; Sheehan, M. R.; Siegel, B.; Kennedy, J.; Marcell, V.; Arnold, A.; more...
    Cold Spring Harbor Molecular Case Studies (2018)

    Fulltext@MSK | Save
  • Resource utilization early after chimeric antigen receptor (CAR) T cell infusion for hematologic malignancies
    Meeting Abstract

    Shah, G. L.; Park, J. H.; Sauter, C. S.; Duck, E.; Halton, E.; Palomba, M. L.; Batlevi, C. L.; Younes, A.; Geyer, M. B.; Smith, E. L.; more...
    Blood (2018)

    Fulltext@MSK | Save
  • Maintenance olaparib following platinum-based chemotherapy in newly diagnosed patients (pts) with advanced ovarian cancer (OC) and a BRCA1/2 mutation (BRCAm): Phase III SOLO1 trial
    Meeting Abstract

    Moore, K. N.; Colombo, N.; Scambia, G.; Kim, B. G.; Oaknin, A.; Friedlander, M.; Lisyanskaya, A.; Floquet, A.; Leary, A.; Sonke, G. S.; more...
    Annals of Oncology (2018)

    Fulltext@MSK | Save
  • A phase I/II study of chemo-immunotherapy with durvalumab (durva) and pegylated liposomal doxorubicin (PLD) in platinum-resistant recurrent ovarian cancer (PROC)
    Meeting Abstract

    O'Cearbhaill, R. E.; Wolfer, A.; Disilvestro, P.; O'Malley, D. M.; Sabbatini, P.; Shohara, L.; Schwarzenberger, P. O.; Ricciardi, T.; Macri, M.; Ryan, A.; more...
    Annals of Oncology (2018)

    Fulltext@MSK | Save
  • Subgroup analysis of rucaparib in platinum-sensitive recurrent ovarian carcinoma: Effect of prior chemotherapy regimens in ARIEL3
    Meeting Abstract

    Lorusso, D.; Coleman, R. L.; Oza, A. M.; Aghajanian, C.; Oaknin, A.; Dean, A.; Colombo, N.; Weberpals, J. I.; Clamp, A. R.; Scambia, G.; more...
    Annals of Oncology (2018)

    Fulltext@MSK | Save
  • Phase 1 study using mogamulizumab (KW-0761) to deplete regulatory T cells in combination with checkpoint inhibitors durvalumab (MEDI4736) or tremelimumab in subjects with advanced solid tumors
    Meeting Abstract

    Zamarin, D.; Hamid, O.; Nayak, A.; Sahebjam, S.; Sznol, M.; Collaku, A.; Fox, F.; Marshall, M.; Hong, D.
    Journal for ImmunoTherapy of Cancer (2018)

    Fulltext@MSK | Save